伊立替康及奥沙利铂联合氟尿嘧啶类药物治疗晚期结直肠癌的缓解率及安全性分析  

Remission rate and safety of irinoticam and oxaliplatin combined with fluorouracil in treatment of advanced colorectal cancer

作　　者：胡晓鸣 Hu Xiaoming(Department of Oncology,Chongqing Xinanlyu Hospital,Chongqing 401326,China)

机构地区：[1]重庆西南铝医院肿瘤科,401326

出　　处：《国际医药卫生导报》2021年第1期92-94,共3页International Medicine and Health Guidance News

摘　　要：目的探讨伊立替康、奥沙利铂联合氟尿嘧啶药物治疗晚期结直肠癌的缓解率及安全性分析。方法选取2016年3月至2019年3月本院收治的晚期结直肠癌患者60例,按照抽签分配原则分为两组,各30例。参照组接受伊立替康+奥沙利铂治疗方案,研究组接受伊立替康+奥沙利铂+氟尿嘧啶类药物治疗方案;比较观察两组患者疗效、并发症发生率和生存质量变化。结果研究组治疗有效率为76.67%(23/30),显著高于参照组53.33%(16/30),差异有统计学意义(P<0.05);两组患者并发症发生率比较,差异无统计学意义(P>0.05);研究组情感功能、生理功能、日常生活、社会功能、认知功能评分分别为(61.28±4.39)分、(58.64±5.27)分、(52.34±5.27)分、(57.36±6.28)分、(64.33±6.27)分,均高于参照组(52.16±5.34)分、(46.39±6.21)分、(41.19±5.36)分、(47.61±5.37)分、(51.28±4.05)分,差异均有统计学意义(均P<0.05)。结论从预后角度出发,给予晚期结直肠癌患者伊立替康+奥沙利铂+氟尿嘧啶类药物治疗方案,治疗效果较为突出,且并发症相对较少,对于提高患者的生存质量具有积极意义。Objective To explore the remission rate and safety of irinoticam and oxaliplatin combined with fluorouracil in treatment of advanced colorectal cancer.Methods Sixty patients with advanced colorectal cancer treated at our hospital from March,2016 to March,2019 were divided into a reference group and a study group by the lottery method,with 30 cases in each group.The reference group were treated with irinoticam and oxaliplatin,and the study group with irinoticam,oxaliplatin,and fluorouracil.The efficacies,incidences of complications,and survival qualities were compared between the two groups. Results The treatment effective rate of thestudy group was significantly higher than that of the reference group [76.67% (23/30) vs. 53.33%(16/30);P<0.05]. There was no statistical difference in the incidence of complications between thereference group and the study group [43.33% (13/30) vs. 30.00% (9/30);P>0.05]. The scores ofemotion function, physical function, daily life, social function, cognitive function were higher in thestudy group than in the reference group [(61.28±4.39) vs. (52.16±5.34), (58.64±5.27) vs. (46.39±6.21), (52.34±5.27) vs. (41.19±5.36), (57.36±6.28) vs. (47.61±5.37), and (64.33±6.27) vs. (51.28±4.05);all P<0.05]. Conclusion Irinoticam and oxaliplatin combined with fluorouracil in treatmentof advanced colorectal cancer has better prognosis and relatively fewer complications, and canimprove the patients, survival quality.

关 键 词：晚期结直肠癌 氟尿嘧啶类药物 疗效 

分 类 号：R735.34[医药卫生—肿瘤]